Next-Gen Avisi Technologies Aims for “One and Done” in a MIGS Device
Avisi’s MIGS device, VisiPlate, has been designed to lower intraocular pressure in patients with moderate to severe glaucoma, a 2.6 million patient market in the US worth billions of dollars. The company believes it doesn’t make tradeoffs between safety and efficacy; it believes it has created an implant that will achieve a durable and effective treatment, once and for all.
Read Article